Aimmune Therapeutics Receives a Buy from Credit Suisse


Credit Suisse analyst Vamil Divan maintained a Buy rating on Aimmune Therapeutics (NASDAQ: AIMT) today and set a price target of $47. The company’s shares opened today at $28.20.

According to TipRanks.com, Divan is ranked 0 out of 5 stars with an average return of -3.3% and a 40.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Eli Lilly & Co, and Portola Pharma.

Currently, the analyst consensus on Aimmune Therapeutics is Strong Buy and the average price target is $59.57, representing an 111.2% upside.

In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $64 price target.

See today’s analyst top recommended stocks >>

Based on Aimmune Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $49.5 million. In comparison, last year the company had a GAAP net loss of $25.87 million.

Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AIMT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts